Labrie F - Search Results

1

Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.

Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Têtu B, Fradet Y, Candas B. Labrie F, et al. Cancer Surv. 1995;23:149-56. Cancer Surv. 1995. PMID: 7621455 Clinical Trial.

2

Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?

Labrie F, Candas B, Gomez JL, Cusan L. Labrie F, et al. Urology. 2002 Jul;60(1):115-9. doi: 10.1016/s0090-4295(02)01639-4. Urology. 2002. PMID: 12100935 Clinical Trial.

3

Combination therapy with flutamide and castration (orchiectomy or LH-RH agonist) in untreated patients with advanced prostate cancer.

Dupont A, Labrie F, Cusan L, Gomez JL, Tremblay M, Lacourcière Y, Emond J, Monfette G. Dupont A, et al. Among authors: labrie f. Recent Results Cancer Res. 1992;124:43-54. doi: 10.1007/978-88-470-2186-0_5. Recent Results Cancer Res. 1992. PMID: 1615218 No abstract available.

4

Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.

Labrie F, Dupont A, Cusan L, Gomez J, Emond J, Monfette G. Labrie F, et al. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):943-50. doi: 10.1016/0960-0760(90)90448-t. J Steroid Biochem Mol Biol. 1990. PMID: 2285608 Clinical Trial.

5

Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.

Cusan L, Gomez JL, Dupont A, Diamond P, Lemay M, Moore S, Labrie F. Cusan L, et al. Among authors: labrie f. Prostate. 1994 May;24(5):257-61. doi: 10.1002/pros.2990240507. Prostate. 1994. PMID: 7513417

6

Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality.

Labrie F, Cusan L, Gomez JL, Diamond P, Candas B. Labrie F, et al. J Clin Endocrinol Metab. 1995 Jul;80(7):2002-13. doi: 10.1210/jcem.80.7.7541800. J Clin Endocrinol Metab. 1995. PMID: 7541800 Review.

7

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy.

Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Dupont A, et al. Among authors: labrie f. J Urol. 1993 Sep;150(3):908-13. doi: 10.1016/s0022-5347(17)35646-x. J Urol. 1993. PMID: 7688437

8

Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide).

Koutsilieris M, Dupont A, Gomez J, Cusan L, Suburu R, Diamond P, Labrie F. Koutsilieris M, et al. Among authors: labrie f. Anticancer Res. 1994 Mar-Apr;14(2B):627-34. Anticancer Res. 1994. PMID: 8010719 Clinical Trial.

9

Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.

Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P. Labrie F, et al. Clin Invest Med. 1993 Dec;16(6):493-8. Clin Invest Med. 1993. PMID: 8013154 Clinical Trial.

10

Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.

Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, et al. Labrie F, et al. Clin Invest Med. 1993 Dec;16(6):499-509. Clin Invest Med. 1993. PMID: 8013155 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

968 results

Search Page

Filters